[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,129,552,512
  • Shares Outstanding, K 941,741
  • Annual Sales, $ 65,179 M
  • Annual Income, $ 20,640 M
  • EBIT $ 31,522 M
  • EBITDA $ 33,519 M
  • 60-Month Beta 0.53
  • Price/Sales 17.77
  • Price/Cash Flow 48.93
  • Price/Book 37.13

Options Overview Details

View History
  • Implied Volatility 39.84% (+0.63%)
  • Historical Volatility 33.52%
  • IV Percentile 70%
  • IV Rank 62.34%
  • IV High 47.67% on 07/30/25
  • IV Low 26.88% on 09/04/25
  • Expected Move (DTE 9) 45.10 (3.78%)
  • Put/Call Vol Ratio 1.05
  • Today's Volume 36,196
  • Volume Avg (30-Day) 46,772
  • Put/Call OI Ratio 1.21
  • Today's Open Interest 366,368
  • Open Int (30-Day) 356,355
  • Expected Range 1,146.64 to 1,236.84

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 29 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $8.98
  • Number of Estimates 5
  • High Estimate $9.26
  • Low Estimate $8.70
  • Prior Year $6.31
  • Growth Rate Est. (year over year) +42.31%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1,052.15 +13.27%
on 06/02/26
1,238.00 -3.74%
on 06/29/26
+109.54 (+10.12%)
since 06/01/26
3-Month
850.51 +40.12%
on 04/29/26
1,238.00 -3.74%
on 06/29/26
+237.22 (+24.85%)
since 04/01/26
52-Week
623.78 +91.05%
on 08/08/25
1,238.00 -3.74%
on 06/29/26
+415.84 (+53.59%)
since 07/01/25

Most Recent Stories

More News
5 Places Investors Can Hide If the AI Trade Keeps Cracking

As AI stocks face volatility, capital is rotating into biotech, industrials, utilities, consumer staples, and dividend ETFs showing relative strength.

XLU : 44.77 (-1.26%)
XLI : 183.36 (-1.01%)
KO : 81.29 (+0.02%)
IBB : 190.12 (-0.04%)
LLY : 1,191.74 (-0.64%)
SCHD : 31.85 (+0.44%)
XLP : 83.30 (+0.28%)
GE : 374.94 (+0.32%)
NEE : 86.37 (-1.60%)
Why Is Eli Lilly (LLY) Stock Soaring Today

Why Is Eli Lilly (LLY) Stock Soaring Today

LLY : 1,191.74 (-0.64%)
TSX Vaults Midday

Canada's main stock index rose on Friday, lifted by gains in mining shares as gold prices rose, while ...

LLY : 1,191.74 (-0.64%)
Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy

The positive opinion is based on results from the Phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials, previously presented at the 2025 American Society of Hematology Annual Meeting and published in The Journal...

LLY : 1,191.74 (-0.64%)
What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management

A new Medicare pathway, the Medicare GLP-1 Bridge program, makes Lilly's obesity medicines – a daily pill or the number 1 most prescribed injectable – accessible to eligible Medicare Part...

LLY : 1,191.74 (-0.64%)
Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders

INDIANAPOLIS , June 24, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Centessa Pharmaceuticals plc. Centessa is a clinical-stage...

LLY : 1,191.74 (-0.64%)
The $11 Billion Reason Abbvie Stock Is Up Today

AbbVie stock rallied today on the $10.9 billion acquisition of Apogee Therapeutics. Here’s how you should play ABBV shares at current levels.

APGE : 132.77 (+0.03%)
JNJ : 253.98 (unch)
LLY : 1,191.74 (-0.64%)
ABBV : 251.06 (-0.23%)
REGN : 624.72 (+0.19%)
SNY : 41.63 (-2.41%)
Lilly declares third-quarter 2026 dividend

INDIANAPOLIS , June 22, 2026 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2026 of $1.73 per share on outstanding common...

LLY : 1,191.74 (-0.64%)
3 Penny Stocks Under $5 Backed by Real Revenue Growth

These three penny stocks under $5 generate real revenue and have catalysts that analysts believe could drive significant upside

LLY : 1,191.74 (-0.64%)
URG : 1.3500 (-0.74%)
GRAB : 3.89 (+3.18%)
ACRS : 5.34 (+0.95%)
3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend

With GLP-1 usage continuing to rise, a group of unlikely beneficiaries is emerging; stocks in the broader health care sector and even in retail could stand out.

TDOC : 9.10 (+7.31%)
NVO : 48.77 (+1.73%)
OZEM : 32.39 (-0.46%)
LLY : 1,191.74 (-0.64%)
DXCM : 68.86 (+2.24%)
OLLI : 75.51 (-1.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure...

See More

Key Turning Points

3rd Resistance Point 1,258.43
2nd Resistance Point 1,237.97
1st Resistance Point 1,214.85
Last Price 1,191.74
1st Support Level 1,171.28
2nd Support Level 1,150.82
3rd Support Level 1,127.70

See More

52-Week High 1,238.00
Last Price 1,191.74
Fibonacci 61.8% 1,003.37
Fibonacci 50% 930.89
Fibonacci 38.2% 858.41
52-Week Low 623.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.